OnKure Therapeutics Reports $59.1M Cash, Reduces Q4 Loss to $13.5M
OnKure held $59.1 million cash at year-end and cut Q4 R&D expenses by $3.6 million, narrowing net loss to $13.5 million. PIKture-01 trial has dosed 71 patients in monotherapy and combination arms with safety and activity data due March 2026, and a pan-mutant candidate announcement set for the same month.
1. Financial Performance Q4 2025
OnKure ended Q4 2025 with $59.1 million cash and cash equivalents, recording R&D expenses of $10.7 million and G&A expenses of $3.4 million. Net loss for the quarter narrowed to $13.5 million, or $0.99 per share, compared to $17.4 million, or $1.37 per share, in Q4 2024.
2. PIKture-01 Trial Progress and Data Timelines
The PIKture-01 Phase 1a/1b trial of OKI-219 has completed enrollment in Parts A and B, dosing 71 patients across monotherapy and fulvestrant combination arms. Part E has dosed 17 patients in the triplet arm with fulvestrant and ribociclib, while Part C enrollment continues, with initial data expected in 2026 and updated safety and activity results due in March 2026.
3. Next-Generation Pan-Mutant Program Outlook
OnKure will announce its next-generation PI3Kα pan-mutant inhibitor candidate for HR+ metastatic breast cancer in March 2026. The company also plans to provide further details on its vascular malformations program later in 2026, leveraging its mutation-selective approach to PI3Kα inhibition.